Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 3;23(21):13431.
doi: 10.3390/ijms232113431.

Role of Non-Coding RNAs in Colorectal Cancer: Focus on Long Non-Coding RNAs

Matteo Lulli  1 , Cristina Napoli  2 , Ida Landini  2 , Enrico Mini  2 , Andrea Lapucci  2
Affiliations
Review

Role of Non-Coding RNAs in Colorectal Cancer: Focus on Long Non-Coding RNAs

Matteo Lulli et al. Int J Mol Sci. .

Abstract

Colorectal cancer is one of the most common causes of cancer-related deaths worldwide. Despite the advances in the knowledge of pathogenetic molecular mechanisms and the implementation of more effective drug treatments in recent years, the overall survival rate of patients remains unsatisfactory. The high death rate is mainly due to metastasis of cancer in about half of the cancer patients and the emergence of drug-resistant populations of cancer cells. Improved understanding of cancer molecular biology has highlighted the role of non-coding RNAs (ncRNAs) in colorectal cancer development and evolution. ncRNAs regulate gene expression through various mechanisms, including epigenetic modifications and interactions of long non-coding RNAs (lncRNAs) with both microRNAs (miRNAs) and proteins, and through the action of lncRNAs as miRNA precursors or pseudogenes. LncRNAs can also be detected in the blood and circulating ncRNAs have become a new source of non-invasive cancer biomarkers for the diagnosis and prognosis of colorectal cancer, as well as for predicting the response to drug therapy. In this review, we focus on the role of lncRNAs in colorectal cancer development, progression, and chemoresistance, and as possible therapeutic targets.

Keywords: chemoresistance; colorectal cancer; diagnosis; gene regulation; long non-coding RNAs; predictive; prognosis; therapeutic targets.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Alteration of lncRNAs molecular mechanisms in CRC initiation, progression, and drug resistance.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Sauer A.G., Fedewa F.A., Butterly L.F., Anderson J.C., Cercek A., Smith R.A., Jemal A. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 2020;70:145–164. doi: 10.3322/caac.21601. - DOI - PubMed
    1. Wang R., Su Q., Yan Z.P. Reconsideration of recurrence and metastasis in colorectal cancer. World J. Clin. Cases. 2021;9:6964–6968. doi: 10.12998/wjcc.v9.i24.6964. - DOI - PMC - PubMed
    1. Pancione M., Giordano G., Remo A., Febbraro A., Sabatino L., Manfrin E., Ceccarelli M., Colantuoni V. Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis. J. Immunol. Res. 2014;2014:686879. doi: 10.1155/2014/686879. - DOI - PMC - PubMed
    1. Garajová I., Ferracin M., Porcellini E., Palloni A., Abbati F., Biasco G., Brandi G. Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer. Int. J. Mol. Sci. 2017;18:1547. doi: 10.3390/ijms18071547. - DOI - PMC - PubMed
    1. Palazzo A.F., Lee E.S. Non-coding RNA: What is functional and what is junk? Front. Genet. 2015;6:2. doi: 10.3389/fgene.2015.00002. - DOI - PMC - PubMed

MeSH terms